- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Truven Health Analytics' Tool to Improve Oncology Outcomes Research
Truven Health Analytics™ today announced it has successfully linked electronic medical records (EMR) and administrative claims data with significant volume to power oncology-focused outcomes research studies. This de-identified data set, the newest addition to the MarketScan® research databases, provides a unique ability for researchers to better understand total healthcare costs, co-morbidities, adverse events, and outcomes for cancer patients by treatment phase, biomarker status, and tumor stage.
“It is exciting to see the pace of development for break-through oncology treatments. As these products come to market, researchers require real-world data to conduct high quality investigations that demonstrate the value of these new treatments.” said Stacey Long, vice president and general manager at Truven Health Analytics. “Payers, providers, and patients want to understand how new treatments affect not only health outcomes, but also overall costs. To do this, researchers need patient-level data that include not only the robust clinical data offered by an oncology EMR, but also the same patient’s claims data to understand associated healthcare costs and the full spectrum of a patient’s care beyond that provided by their oncologist. We are delighted to be able to offer this ground-breaking capability to the healthcare research community.”
Read the press release here: http://bit.ly/1p7xt53
Source: Digital Journal
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
